Sandoz, a global leader in biosimilars and generic medicines, has announced a significant investment in a new drug substance facility located in Ljubljana, Slovenia. This strategic move aims to expand the company’s biosimilar manufacturing capacity, reinforcing its commitment to increasing access to affordable, high-quality medicines worldwide. The state-of-the-art facility is expected to enhance production capabilities and support Sandoz’s growing portfolio of biosimilar therapies, marking a pivotal step in the company’s ongoing efforts to meet rising global demand.
Sandoz Strengthens Biosimilar Production with New Ljubljana Facility
Sandoz has officially expanded its global footprint with the launch of a cutting-edge drug substance manufacturing facility in Ljubljana, Slovenia. This strategic investment is positioned to significantly increase the company’s capacity to produce high-quality biosimilars, reinforcing its commitment to making advanced therapies…
—-
Author : Ava Thompson
Publish date : 2026-09-27 12:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
